Expansion of a GGGGCC repeat in C9orf72 causes amyotrophic lateral sclerosis, frontotemporal dementia, or a combination of both. Bidirectional repeat transcripts sequester RNA-binding proteins into nuclear RNA foci. The repeat is translated into dipeptide repeat (DPR) proteins that are crucial for repeat-induced toxicity. DPRs inhibit the proteasome and sequester other proteins. These changes are accompanied by widespread brain atrophy and subclinical cognitive impairment before disease onset. Both repeat RNA and DPRs impair nucleocytoplasmic transport and promote TDP-43 mislocalization and aggregation. Thus, repeat RNA and DPRs may gradually trigger TDP-43 pathology and subsequent region-specific neurodegeneration in a cascade similar to amyloid-b peptide in Alzheimer's disease. The key components of the C9orf72 cascade are promising therapeutic targets in different disease stages. 
Introduction
Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are two fatal neurodegenerative diseases that overlap clinically, genetically and pathologically [1, 2] . Degeneration of the frontotemporal lobes results in behavioral disinhibition, dementia and speech and language impairments, depending on which regions are most affected. Loss of the upper and lower motoneurons in the motor cortex and the spinal cord causes progressive paralysis and ultimately respiratory failure. Genetic and neuropathological findings suggest that both diseases are opposite ends of a disease spectrum and many patients suffer from combined symptoms. Neuropathologically, ALS and FTD are classified depending on the key aggregating proteins. TDP-43 inclusions are found in 60% of FTD and about 90% of ALS patients, specifically in neurons and glia in the areas with the most severe neurodegeneration [3] . Rare TDP-43 mutations have been found to cause predominantly ALS [4] , but most inherited forms of ALS or FTD with TDP-43 pathology are due to mutations in several other genes, most commonly in GRN (in FTD) and C9orf72 (in ALS and FTD) [5, 6] . A massive expansion of a GGGGCC repeat (with up to several thousand repeats compared to fewer than 25 in controls) upstream of the coding region of C9orf72 (Figure 1a ) is the most common ALS/FTD causing mutation among Caucasians [7] [8] [9] . Repeat expansions cause equally likely ALS, FTD or a mixture of both and are found in 5-40% of familial ALS and FTD cases and in 5% seemingly sporadic patients [10, 11] .
Pathomechanisms
Several pathomechanisms have been proposed for C9orf72 ALS and FTD that may act in concert. These include: Firstly, haploinsufficiency; secondly, RNA toxicity, and finally, toxicity of highly unusual protein deposits.
Many studies show reduced mRNA expression in C9orf72 ALS/FTD cases [7] [8] [9] that was recently confirmed on the C9orf72 protein level [12] , suggesting haploinsufficiency as a cause of ALS/FTD. However, the physiological function of the C9orf72 protein is poorly understood and neuron specific knockout mice develop no disease like pathology [13] making it unlikely that haploinsufficiency significantly contributes to the disease mechanism.
The presence of nuclear foci of the repeat RNA (Figure 1b) suggests that sense and antisense transcripts of the repeat sequester specific RNA-binding proteins, which may profoundly alter RNA-metabolism. Several (ggggcc) n and (ccccgg) n interacting proteins (lower case denotes RNA) have been identified in vitro, including hnRNPA3 [14] , SRSF2, hnRNP H1/F, ALYREF [15] , ADARB2 [16 ] and Nucleolin [17] .
Pathologically, C9orf72 mutation cases show specific star-shaped or dot-like TDP-43 negative, p62-positive cytoplasmic inclusions, which are not found in other ALS/FTD cases [18] . The core components of these inclusions are derived from unconventional translation of the intronic repeat RNA in all reading frames into five aggregating dipeptide repeat (DPR) proteins (Figure 1a ,c) [19 ,20 ,21-23] . Virtually all TDP-43 negative inclusions contain poly-GA. The other DPR species coaggregate to a variable extent in these inclusions. Poly-GP and poly-GR are found in about half of the aggregates, while the antisense transcript-derived poly-PA and poly-PR are much rarer.
Repeat-associated non-ATG (RAN) translation was first discovered for (cag) n expansions and is thought to involve hairpin formation of the repeat mRNA [24] . Recently, RAN translation of an expanded (cgg) n repeat was also observed in fragile X tremor ataxia syndrome [25] . It is still unclear how repetitive RNA hairpins can overcome the tight control mechanisms during translation initiation, but interfering with the secondary structure has been shown to reduce translation of the C9orf72 repeat [26 ] .
100 Neurobiology of disease In this review we try to reconcile mechanistic insights from cellular and animal models and findings from neuropathological and clinical studies. Furthermore, we unify these findings into a pathological cascade with surprising similarities to the amyloid cascade in Alzheimer's disease (AD).
A major role of C9orf72 loss of function in ALS/FTD is unlikely
Although reduction of C9orf72 transcripts has been described already in the initial reports of the C9orf72 repeat expansion (and widely replicated afterwards), it remains unclear whether haploinsufficiency contributes to C9orf72 pathogenesis. Data on promoter hypermethylation even suggest that reduced C9orf72 expression is neuroprotective, because methylation correlates with prolonged survival [27] .
Neuron specific conditional knockout of C9orf72 in mice leads to an unexplained weight loss, but does not cause motor symptoms, TDP-43 pathology, neurodegeneration, neuroinflammation or premature death [13] , although this does not exclude a non-neuronal component of haploinsufficiency. Moreover, sustained reduction of C9orf72 expression by antisense oligonucleotides (ASO) in mouse brain did not result in ALS/FTD like symptoms [28 ] . Thus, C9orf72 loss of function does not seem to cause TDP-43 associated neurodegeneration and is unlikely to be the main cause of ALS/FTD.
To fully address a possible loss of function component, a better understanding of the C9orf72 function is crucial. Unfortunately, antibodies detecting endogenous C9orf72 are notoriously difficult to generate, which may be due to the low endogenous expressions levels. C9orf72 protein levels are about 200-fold lower than the levels of TDP-43 and FUS in motor neurons and various cell lines [29] . Homology searches identified a putative DENN (Differentially Expressed in Normal and Neoplasia) domain in C9orf72 suggesting it acts as a guanine nucleotide exchange factor (GEF) for small GTPases, particularly within the Rab protein family [30] . Indeed, partial colocalization of C9orf72 with Rab1/5/7/11 endo-lysosomes was reported, which suggests that C9orf72 might regulate protein degradation and autophagy [31] . In contrast, antibodies to the short isoform have been reported to label the nuclear envelop in healthy controls and the plasma membrane in ALS cases with or without C9orf72 mutation indicating a general defect in nuclear trafficking in ALS [32] which may be interesting in regard to the nuclear transport deficiencies recently reported as a pathological consequence of C9orf72 repeat expansions (see below).
Gain of function models resemble patient pathology best
Many groups have reported toxic gain of function of the C9orf72 repeat expansion in cellular and animal models that to various degrees invoke either DPR, RNA toxicity, or both. iPSC-derived neurons from C9orf72 patients consistently show RNA foci, but lack abundant compact DPR inclusions, while DPR protein expression is often detectable at low level [16 ,33-35] . Most likely inclusion formation is a slow process due to inefficient non-ATG translation of the DPR proteins. Several groups reported subtle changes in gene expression in patient derived fibroblasts and neurons, but the different studies show little overlap [16 ,28 ,35] . Neurons carrying the repeat expansion are initially hyperexcitable [16 ] and become hypoexcitable later in development [34, 35] which may lead to the functional inactivation of motoneurons before cell death. In patient derived neurons, ASOs targeting the repeat or the C9orf72 gene reduce RNA foci surprisingly without affecting poly-GP expression and restored normal gene expression arguing for predominant RNA toxicity [16 ] , although this may also be explained by a long half-life of poly-GP. Similarly, ASOs have been shown to inhibit RNA foci formation in patient fibroblasts, but did not correct altered gene expression in this case [28 ] .
To dissect the role of RNA and protein toxicity, several groups expressed endogenous ggggcc-repeat sequence or used ATG-initiated synthetic genes where the ggggccrepeat was replaced by alternative codons for expression of individual DPR proteins in cellular models, suggesting poly-GA is the most aggregation prone DPR protein within cells [21, [36] [37] [38] [39] [40] . Nearly all reports observed p62-positive cytoplasmic inclusions like those found in C9orf72 patients only upon poly-GA expression [21, [36] [37] [38] [39] . In many reports this was associated with toxicity. Poly-GA neurotoxicity has been attributed to impaired function of the ubiquitin proteasome system and sequestration of Unc119, a protein regulating the trafficking of myristoylated cargo proteins [36] [37] [38] . Two inhibitors of ER stress, salubrinal and TUDCA, were able to rescue poly-GA toxicity [37] . In contrast, poly-GR and poly-PR expression typically resulted in nucleolar inclusions and also induced toxicity [38, 39, 41] . While poly-GR and poly-PR toxicity was stronger than poly-GA toxicity in many systems, we could not detect such nucleolar poly-GR/PR inclusions in patient tissue using monoclonal antibodies [42] . Poly-GR/PR may interfere with RNA metabolism and protein synthesis by directly binding RNA, particularly in the nucleolus through repetitive arginine residues [39, 41] . Importantly, co-expression of poly-GA and poly-GR recruits poly-GR into cytoplasmic inclusions and partially rescues its toxicity in a model with predominantly diffuse cytoplasmic GR 80 expression [43] indicating that the toxicity of poly-GR depends is on its localization. Sense strand repeat expression without start codon had little effect in most cellular models [36, 39] , while antisense repeat expression has been linked to toxicity [21] .
In Drosophila, however, expression of ggggcc-repeats of increasing length causes degeneration in the eye that is largely caused by DPR protein expression, because it is completely prevented by stop codons interspaced in the repeat [44 ] . While expression of poly-GR and poly-PR from synthetic genes throughout the nervous system caused early lethality, poly-GA expression still significantly shortened the life span of transgenic flies. In another report, diffuse cytoplasmic GR 80 expression specifically in the fly wing causes a classic notching phenotype that can be rescued by expressing the membranetethered transcription factor Notch [43] . At least in flies, cytoplasmic ggggcc-repeat RNA derived from poly-A tailed expression is far more toxic than nuclear repeat RNA derived from intronic expression, which has been attributed to enhanced DPR expression of the RNA exported from the nucleus [45] .
Three recent reports found that modulation of nuclear transport in flies and yeast suppresses toxicity of repeat RNA and/or poly-GR/PR [46 ,47 ,48 ] . Expression of the sense repeat in the fly eye induced toxicity with partial mislocalization of the fly TDP-43 homology (TBPH) protein, although poly-GR and poly-GP expression was not detected in this model [46 ] . The sense repeat RNA binds to and inhibits RanGAP and thus disturbs the nucleocytoplasmic Ran gradient critical for the localization of many other proteins and RNAs, because only RanGDP but not RanGTP is imported into the nucleus. Enhancing nuclear import using overexpression of RanGAP or Importin-a suppresses neurodegeneration. Interestingly, RanGAP normally shows smooth perinuclear staining whereas RanGAP aggregates are found along the nuclear envelope in iPSC derived neurons and tissue from C9orf72 mutation cases [46 ] . Moreover, in an unbiased screen in ggggcc-expressing flies Freibaum and colleagues identified 18 enhancers and suppressors that encode components of the nuclear pore complex (NPC) [47 ] . This group observed poly-GP and poly-GR, but no poly-GA expression. Boosting nuclear import by expression of karyopherins also rescues poly-PR toxicity in yeast suggesting that the ggggcc-repeat RNA and poly-GR/PR cause toxicity by disrupting nucleocytoplasmic transport [48 ] . Interestingly, nucleocytoplasmic transport seems to be affected in ALS patients without C9orf72 mutation and may therefore be a common feature of ALS [32, 49] . In line with that, ALS causing mutations affect the PY-NLS of FUS and lead to its accumulation within the cytosol and its subsequent aggregation [50] .
The best mouse model so far is based on AAV-mediated (ggggcc) 66 expression [51 ] . Six months after neonatal intracerebroventricular injection, nuclear RNA foci and intranuclear and cytoplasmic poly-GA/GP/GR inclusions were detected together with diffuse nuclear poly-GP and diffuse cytoplasmic poly-GR. These mice show mild neuronal loss and deficits in the Rota-Rod assay, suggesting impaired motor coordination or balance. Importantly, this is the first C9orf72 model displaying prominent TDP-43 aggregates and thus most closely resembles C9orf72 ALS/ FTD patients. Cells with TDP-43 aggregates always had visible RNA foci, while poly-GA inclusions were present in 75% of these cells. Similarly, we recently generated a cell culture model by high-level expression of a (ggggcc) 80 repeat without start codons that co-expresses all DPRs and showed cytoplasmic redistribution of TDP-43 (Mori et al., unpublished).
The first cellular and animal models clearly highlight the importance of toxic gain of function as the origin of TDP-43 aggregation and neurodegeneration. Particularly, poly-GR/PR and to a lesser extent poly-GA are neurotoxic in vitro and in vivo, but only aggregates in the poly-GA models resemble the inclusions found in patients. It will be critical to determine, which of the mechanisms of RNA and DPR toxicity seen in model systems contribute to pathogenesis in patients.
Lack of spatial correlation of DPR deposits with TDP-43 pathology and neurodegeneration
The distribution of sense and antisense RNA foci and interacting proteins has not been rigorously studied in large cohorts of ALS and FTD cases. One possible reason might be that these tiny structures are only visible in large magnifications and would require great effort for quantitative analysis of several brain regions in many patients. A recent study found that only antisense, but not sense RNA foci correlated with pathological nuclear clearance of TDP-43 in motoneurons [52] .
Regardless of clinical or neuropathological diagnosis, poly-GA/GP/GR inclusions are widespread throughout the neocortex, hippocampus, cerebellum and thalamus and rare in the spinal cord including motor neurons [23,42,53 ,54,55] . Thus, DPR distribution is not spatially correlated with the areas of most prominent neurodegeneration in ALS and FTD cases. Interestingly, the distribution of amyloid plaques also poorly correlates with the neurodegeneration and clinical progression in AD cases [56] . However, recently some clinical correlates of DPR deposits have been found in C9orf72 mutant cohorts. Higher poly-GA load is associated with earlier age of onset [54] . Cases with FTD with or without additional signs of motoneuron disease show more cerebellar poly-GA inclusions than cases with pure motoneuron disease [42] . Poly-PR has been reported to preferentially aggregate in motor neurons [52] , but this has not been confirmed by us and others [42, 55] . Several FTD cases with abundant DPR but without TDP-43 pathology have been identified, strongly arguing that DPR pathology contributes at least to the early symptoms of C9orf72 patients [19 ,57,58] .
In contrast to DPR pathology, the distribution of TDP-43 pathology is highly correlated with areas of neurodegeneration and clinical symptoms [3, 53 ]. Thus, TDP-43 mislocalization and/or aggregation are the most likely effectors of C9orf72 repeat associated toxicity, although a causal relation is not formally proven and the mechanistic link is not fully resolved. Interestingly, pathogenic TDP-43 mutations cause predominantly regional TDP-43 pathology similar to sporadic ALS/FTD cases indicating that motoneurons and the frontotemporal cortex are especially susceptible to cytoplasmic TDP-43 aggregation [59] . Therefore, Dormann and Haass formulated a multiple hit hypothesis where additional stressors must induce the irreversible deposition of TDP-43 following initial cytoplasmic mislocalization [1] . We speculate that DPR proteins and repeat RNA are such stressors that promote TDP-43 pathology in C9orf72 patients.
Cross-sectional analysis of C9orf72 patients reveals widespread brain atrophy and early cognitive deficits
Recent clinical data may help to reconcile the conflicting findings on DPR toxicity in model systems and neuropathological analysis. In Alzheimer's disease, cross-sectional analysis of individuals carrying pathogenic mutations revealed changes in biomarkers, imaging parameters and cognitive tests many years before clinical dementia and established the concept of prodromal disease stages [60] . Similarly, the GENFI consortium analyzed presymptomatic changes in individuals carrying FTD-causing mutations in C9orf72, GRN or MAPT and normalized the data to the average age of onset within each family [61 ] . While all carriers showed impairment in neuropsychological tests several years before developing clinical FTD/ALS, C9orf72 carriers showed detectable impairment 5-15 years earlier than the GRN or MAPT patients. Moreover, while volumetric imaging data support discrete atrophy in the insula and temporal cortex 5-10 years before the expected age of onset independent of the mutation, C9orf72 patients showed widespread atrophy in the neocortex and thalamus already 20-25 years before the expected disease onset. Since TDP-43 pathology is largely limited to the frontotemporal cortex and the motor cortex, the clinical findings argue for an early role of the widely expressed DPR inclusions and/or RNA . The repeat RNA is translated by an unconventional mechanism into five DPR species that interfere with the function of Unc119 and the ubiquitin proteasome system (UPS). Both repeat RNA and DPR proteins impair function of the nuclear pore complex (NPC). All these pathways may already impair neuronal function and induce widespread presymptomatic brain atrophy. In combination these pathways trigger TDP-43 mislocalization and aggregation, which ultimately leads to rapid neurodegeneration. Insets show RNA foci (arrow, like in Figure 1b) and immunostainings of poly-GA aggregates and phospho-TDP-43 aggregates. Reduced C9orf72 protein expression may further contribute to pathogenesis by unidentified mechanisms.
foci in the presymptomatic brain atrophy in C9orf72 cases.
An amyloid-like cascade model of C9orf72 pathogenesis
Together these findings led us to postulate a cascade hypothesis for C9orf72 associated ALS/FTD in approximate analogy to the amyloid cascade hypothesis for Alzheimer's disease [56, 62, 63] . Increased production, aggregation or failure of clearance of the amyloid b-peptide (Ab) is the most likely initial trigger of the disease (Figure 2a) . Accumulation of soluble Ab species, subtle synaptic dysfunction and insoluble Ab plaques induce an inflammatory response, which may result in microglial dysfunction and an early cognitive dysfunction in neuropsychological tests [60] . Then, a misbalance of kinases and phosphates boosts abnormal phosphorylation of tau and its subsequent aggregation and deposition in tangles. Tau aggregates or oligomers further impair synaptic function and cause neuronal loss by incompletely defined mechanisms. Importantly, Ab pathology arises decades before the onset of dementia in the neocortex and then spreads centripetally towards the brain stem. By the time of diagnosis Ab pathology has reached a plateau and poorly correlates with disease progression similar to DPR pathology in ALS/FTD. In contrast, the progression of Tau pathology from the (trans)entorhinal cortex to the neocortex correlates well with the clinical progression of dementia.
In line with Ab plaques, we postulate that DPR proteins and toxic RNA may trigger a deadly cascade decades before clinical symptoms occur. Most likely, several cell autonomous and non-cell autonomous mechanisms act in concert. Sequestration of RNA-binding proteins, impairment of nuclear import and transcriptional alterations may lead to TDP-43 hyperphosphorylation, mislocalization and reduced excitability of neurons. DPR proteins may promote TDP-43 aggregation by inhibiting the proteasome and further altering RNA metabolism and nuclear transport. This is in line with the multiple hit model for FUS and TDP-43 aggregation in ALS/FTD [1] . We speculate that DPR aggregates could induce neuroinflammation which may further enhance TDP-43 aggregation. Neuronal cell death could then be induced by cytosolic accumulation of abnormally phosphorylated TDP-43 in analogy to abnormally phosphorylated tau. Thus, the lack of correlation of Ab plaques and DPR inclusion density with neurodegeneration may be explained by triggering a slow cascade before clinical disease onset that can later sustain itself independent of its trigger as it has been postulated for AD [56] .
According to our cascade model, three strategic points appear most suited for therapeutic intervention. First, preventing initiation of the disease cascade right at the top, for example, by enhancing repeat RNA degradation or preventing its translation using ASOs [16 ,28 ] . Second, preventing the conversions from presymptomatic to symptomatic stage by targeting DPR or RNA toxicity to block initiation of TDP-43 mislocalization, for example, by boosting DPR degradation or by modulating the structure of the repeat RNA-repeat or by restoring nuclear transport [26 ,46 ,47 ,48 ] . Third, targeting common downstream mechanisms not limited to ALS and FTD cases with C9orf72 mutation, for example, by inhibiting TDP-43 aggregation and toxicity or modulating inflammation. This concept highlights the need for combination of different drugs in the prodromal and later stages of C9orf72 ALS/FTD.
